GABRA1
ENSG00000022355
Target class
Ion channel
Chromosome
5
Approved drugs
58
Clinical candidates (approved and in development)
70
- Approved drugs
- 58
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 70
- Chemical probe available
- No
- Other names
- EJM5
- Target name
- GABRA1
- Gene name
- Gamma-aminobutyric acid type A receptor subunit alpha1
- Gene symbol
- GABRA1
- Protein name
- Gamma-aminobutyric acid receptor subunit alpha-1 (GABA(A) receptor subunit alpha-1) (GABAAR subunit alpha-1)
- Gene biotype
- Protein coding
- Gene family
- Gamma-aminobutyric acid type A receptor subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 12
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 82.71
- Tissue specificity (Gini)
- 0.894
- Tissue specificity (tau)
- 0.951
- KEGG gene identifiers
- hsa:2554
- Protein interaction confidence
- 0.832706
- Protein interaction partners
- 34
- R-HSA-1236394
- R-HSA-977443
- End position
- 161899981
- Start position
- 161847063
- Chromosome
- 5
- Strand
- Forward
- Postsynaptic cell membrane
- Multi-pass membrane protein . Cell membrane
- Multi-pass membrane protein . Cytoplasmic vesicle membrane
- Multi-pass membrane protein . Note=Mainly located in GABAergic synapses in granule cells, and also in the extrasynaptic membrane at a lower concentration. .
- Plasma membrane
- PubMed 29950725
- PubMed 2465923
- PubMed 25489750
- Tissue specificity (tau)
- 0.951111
- Expression inequality (Gini)
- 0.893764
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 82.71
- Brain - Frontal Cortex (BA9)
- 58.46
- Brain - Cerebellum
- 55.67
- Brain - Cortex
- 31.14
- Brain - Anterior cingulate cortex (BA24)
- 23.3
Expression in transcripts per million
- Brain - Cerebellar Hemisphere82.71
- Brain - Frontal Cortex (BA9)58.46
- Brain - Cerebellum55.67
- Brain - Cortex31.14
- Brain - Anterior cingulate cortex (BA24)23.3
- Brain - Hippocampus8.45
- Brain - Hypothalamus8.18
- Brain - Amygdala7.79
- Brain - Nucleus accumbens (basal ganglia)7.75
- Brain - Caudate (basal ganglia)4.7
- Brain - Putamen (basal ganglia)4.06
- Brain - Substantia nigra3.38
- Brain - Spinal cord (cervical c-1)0.96
- Testis0.17
- Stomach0.08
- Pituitary0.07
- Prostate0.02
- Spleen0.02
- Colon - Sigmoid0.01
- Adrenal Gland0.01
- Colon - Transverse0.01
- Adipose - Visceral (Omentum)0.01
- Lung0.01
- Small Intestine - Terminal Ileum0.01
- Thyroid0.01
And 29 more, listed on the interactive page.
- GO:0007214
- GO:0051932
- GO:1902476
- GO:1904862
- GO:0005886
- GO:0043197
- GO:1902711
- GO:0004890
- GO:0022851
decreased sleep
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased sleep
- central nervous system
- cardiovascular
PubMed 28216264increased eating
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased eating
- central nervous system
- cardiovascular
PubMed 28216264decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- central nervous system
- cardiovascular
PubMed 28216264decreased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased body temperature
- central nervous system
- cardiovascular
PubMed 28216264decreased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pain
- central nervous system
- cardiovascular
PubMed 28216264convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: convulsions
- central nervous system
- cardiovascular
PubMed 28216264ataxia
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: ataxia
- central nervous system
- cardiovascular
PubMed 28216264increased cardiac output
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased cardiac output
- central nervous system
- cardiovascular
PubMed 28216264decreased cardiac contractility
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased cardiac contractility
- central nervous system
- cardiovascular
PubMed 28216264drug abuse/dependence
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: drug abuse/dependence
- central nervous system
- cardiovascular
PubMed 28216264decreased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased memory
- central nervous system
- cardiovascular
PubMed 28216264decreased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased convulsions
- central nervous system
- cardiovascular
PubMed 28216264decreased locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased locomotor activity
- central nervous system
- cardiovascular
PubMed 28216264muscle relaxation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: muscle relaxation
- central nervous system
- cardiovascular
PubMed 28216264decreased anxiety
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased anxiety
- central nervous system
- cardiovascular
PubMed 28216264increased respiratory rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased respiratory rate
- central nervous system
- cardiovascular
PubMed 28216264increased sleep
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased sleep
- central nervous system
- cardiovascular
PubMed 28216264
seizure (when used as a BZD antidote)
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: seizure (when used as a BZD antidote)
Biological samples
- central nervous system
PubMed 23197038muscle relaxation
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: muscle relaxation
Biological samples
- central nervous system
PubMed 23197038dizziness
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: dizziness
Biological samples
- central nervous system
PubMed 23197038anterograde amnesia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: anterograde amnesia
Biological samples
- central nervous system
PubMed 23197038abuse potential
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: abuse potential
Biological samples
- central nervous system
PubMed 23197038sedation
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: sedation
Biological samples
- central nervous system
PubMed 23197038depression
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: depression
Biological samples
- central nervous system
PubMed 23197038anxiolysis
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: anxiolysis
Biological samples
- central nervous system
PubMed 23197038ataxia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: ataxia
Biological samples
- central nervous system
PubMed 23197038anticonvulsant
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: anticonvulsant
Biological samples
- central nervous system
PubMed 23197038
Related records
Trials (4,014)
- "Chou's Tiaoshen" Acupoints for Short-term Insomnia.
- "Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
- 1-1-8 Wash-in for Sevoflurane Low Flow Anesthesia
- 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
- 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)
- 3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion
- 50% Effective Concentration of Sevoflurane for Immobility
- 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
- A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006
- A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A Better Choice for Patients Undergoing Endovascular Coil Embolization
- A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)
- A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 in ICU Patients Undergoing Long-Term Mechanical Ventilation
- A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery
- A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
Drugs (81)
- ABP-700 GABA-A receptor; anion channel agonist
- Acamprosate GABA-A receptor; anion channel positive modulator
- Acamprosate calcium GABA-A receptor; anion channel positive modulator
- Adipiplon GABA-A receptor; anion channel partial agonist
- Alprazolam GABA-A receptor; anion channel positive allosteric modulator
- Brexanolone GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital sodium GABA-A receptor; anion channel positive allosteric modulator
- Butalbital GABA-A receptor; anion channel positive allosteric modulator
- Cenobamate GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide hydrochloride GABA-A receptor; anion channel positive allosteric modulator
- Cipepofol GABA-A receptor; anion channel agonist
- Clobazam GABA-A receptor; anion channel positive allosteric modulator
- Clomethiazole GABA-A receptor; anion channel positive allosteric modulator
- Clonazepam GABA-A receptor; anion channel positive allosteric modulator
- Clorazepate dipotassium GABA-A receptor; anion channel positive allosteric modulator
- Clorazepic acid GABA-A receptor; anion channel positive allosteric modulator
- Clotiazepam GABA-A receptor; anion channel positive allosteric modulator
- Darigabat GABA-A receptor; anion channel agonist